News & Updates

Functional anorectal pain ups incidence of ED, depression, anxiety in men
Functional anorectal pain ups incidence of ED, depression, anxiety in men
27 Aug 2023
QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
26 Aug 2023 byJairia Dela Cruz

In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.

QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
26 Aug 2023